Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Suzanne Eleanor Dahlberg, Ph.D.

Title
Institution
Department
Address
Profile Picture

Biography
Harvard UniversityPhD2005Biostatistics

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Barsky EE, Berbert LM, Dahlberg SE, Truog RD. Attitudes towards involving children in decision-making surrounding lung transplantation. Pediatr Pulmonol. 2021 Feb 15. PMID: 33586869.
    Citations:    Fields:    
  2. Steuer CE, Jegede OA, Dahlberg SE, Wakelee HA, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Butts CA, Ramalingam SS, Schiller JH. Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial. J Thorac Oncol. 2021 Feb 01. PMID: 33539971.
    Citations:    Fields:    
  3. Pitts S, Dahlberg SE, Gallagher JS, Gordon CM, DiVasta AD. Is Ovarian Reserve Impacted in Anorexia Nervosa? J Pediatr Adolesc Gynecol. 2021 Apr; 34(2):196-202. PMID: 33278562.
    Citations:    Fields:    
  4. Steffen McLouth LE, Zhao F, Owonikoko TK, Feliciano JL, Mohindra NA, Dahlberg SE, Wade JL, Srkalovic G, Lash BW, Leach JW, Leal TA, Aggarwal C, Cella D, Ramalingam SS, Wagner LI. Patient-reported tolerability of veliparib combined with cisplatin and etoposide for treatment of extensive stage small cell lung cancer: Neurotoxicity and adherence data from the ECOG ACRIN cancer research group E2511 phase II randomized trial. Cancer Med. 2020 10; 9(20):7511-7523. PMID: 32860331.
    Citations: 1     Fields:    
  5. Dahlberg SE, Korn EL, Le-Rademacher J, Mandrekar SJ. Clinical Versus Statistical Significance in Studies of Thoracic Malignancies. J Thorac Oncol. 2020 09; 15(9):1406-1408. PMID: 32580055.
    Citations: 1     Fields:    Translation:Humans
  6. Cooper AJ, Kobayashi Y, Kim D, Clifford SE, Kravets S, Dahlberg SE, Chambers ES, Li J, Rangachari D, Nguyen T, Costa DB, Rabin MS, Wagle N, Sholl LM, Jänne PA, Oxnard GR. Identification of a RAS-activating TMEM87A-RASGRF1 Fusion in an Exceptional Responder to Sunitinib with Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 08 01; 26(15):4072-4079. PMID: 32312893.
    Citations:    Fields:    
  7. Hida T, Dahlberg SE, Lydon CA, Hatabu H, Johnson BE, Awad MM, Nishino M. Tumor Volume Analysis as a Predictive Marker for Prolonged Survival in Anaplastic Lymphoma Kinase-rearranged Advanced Non-Small Cell Lung Cancer Patients Treated With Crizotinib. J Thorac Imaging. 2020 Mar; 35(2):101-107. PMID: 30985604.
    Citations: 3     Fields:    Translation:Humans
  8. Ivanova E, Kuraguchi M, Xu M, Portell AJ, Taus L, Diala I, Lalani AS, Choi J, Chambers ES, Li S, Liu S, Chen T, Barbie TU, Oxnard GR, Haworth JJ, Wong KK, Dahlberg SE, Aref AA, Barbie DA, Bahcall M, Paweletz CP, Jänne PA. Use of ExVivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non-Small Cell Lung Cancer. Clin Cancer Res. 2020 05 15; 26(10):2393-2403. PMID: 32034078.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  9. Nishino M, Hida T, Kravets S, Dahlberg SE, Lydon CA, Hatabu H, Johnson BE, Awad MM. Tumor volume dynamics and tumor growth rate in ALK-rearranged advanced non-small-cell lung cancer treated with crizotinib. Eur J Radiol Open. 2020; 7:100210. PMID: 33102632.
    Citations:    
  10. Ramalingam SS, Dahlberg SE. Reply to N. Hanna et al and L. Xie et al. J Clin Oncol. 2020 03 01; 38(7):771-772. PMID: 31895616.
    Citations:    Fields:    Translation:Humans
  11. Vokes NI, Liu D, Ricciuti B, Jimenez-Aguilar E, Rizvi H, Dietlein F, He MX, Margolis CA, Elmarakeby HA, Girshman J, Adeni A, Sanchez-Vega F, Schultz N, Dahlberg S, Zehir A, Jänne PA, Nishino M, Umeton R, Sholl LM, Van Allen EM, Hellmann MD, Awad MM. Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2019; 3. PMID: 31832578.
    Citations: 9     
  12. Aguilar EJ, Ricciuti B, Gainor JF, Kehl KL, Kravets S, Dahlberg S, Nishino M, Sholl LM, Adeni A, Subegdjo S, Khosrowjerdi S, Peterson RM, Digumarthy S, Liu C, Sauter J, Rizvi H, Arbour KC, Carter BW, Heymach JV, Altan M, Hellmann MD, Awad MM. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression. Ann Oncol. 2019 10 01; 30(10):1653-1659. PMID: 31435660.
    Citations: 30     Fields:    Translation:Humans
  13. Gill RR, Tsao AS, Kindler HL, Richards WG, Armato SG, Francis RJ, Gomez DR, Dahlberg S, Rimner A, Simone CB, de Perrot M, Blumenthal G, Adjei AA, Bueno R, Harpole DH, Hesdorffer M, Hirsch FR, Pass HI, Yorke E, Rosenzweig K, Burt B, Fennell DA, Lindwasser W, Malik S, Peikert T, Mansfield AS, Salgia R, Yang H, Rusch VW, Nowak AK. Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. J Thorac Oncol. 2019 10; 14(10):1718-1731. PMID: 31470129.
    Citations: 1     Fields:    Translation:Humans
  14. Ramalingam SS, Dahlberg SE, Belani CP, Saltzman JN, Pennell NA, Nambudiri GS, McCann JC, Winegarden JD, Kassem MA, Mohamed MK, Rothman JM, Lyss AP, Horn L, Stinchcombe TE, Schiller JH. Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508. J Clin Oncol. 2019 09 10; 37(26):2360-2367. PMID: 31361535.
    Citations: 15     Fields:    Translation:Humans
  15. Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM. Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. J Clin Oncol. 2019 08 01; 37(22):1927-1934. PMID: 31206316.
    Citations: 38     Fields:    Translation:Humans
  16. To C, Jang J, Chen T, Park E, Mushajiang M, De Clercq DJH, Xu M, Wang S, Cameron MD, Heppner DE, Shin BH, Gero TW, Yang A, Dahlberg SE, Wong KK, Eck MJ, Gray NS, Jänne PA. Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. Cancer Discov. 2019 07; 9(7):926-943. PMID: 31092401.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  17. Awad MM, Leonardi GC, Kravets S, Dahlberg SE, Drilon A, Noonan SA, Camidge DR, Ou SI, Costa DB, Gadgeel SM, Steuer CE, Forde PM, Zhu VW, Fukuda Y, Clark JW, Jänne PA, Mok T, Sholl LM, Heist RS. Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis. Lung Cancer. 2019 07; 133:96-102. PMID: 31200835.
    Citations: 13     Fields:    Translation:Humans
  18. Araki T, Dahlberg SE, Hida T, Lydon CA, Rabin MS, Hatabu H, Johnson BE, Nishino M. Interstitial lung abnormality in stage IV non-small cell lung cancer: A validation study for the association with poor clinical outcome. Eur J Radiol Open. 2019; 6:128-131. PMID: 30984804.
    Citations: 5     
  19. Ricciuti B, Kravets S, Dahlberg SE, Umeton R, Albayrak A, Subegdjo SJ, Johnson BE, Nishino M, Sholl LM, Awad MM. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. J Immunother Cancer. 2019 03 28; 7(1):87. PMID: 30922388.
    Citations: 14     Fields:    Translation:Humans
  20. Park H, Dahlberg SE, Lydon CA, Araki T, Hatabu H, Rabin MS, Johnson BE, Nishino M. M1b Disease in the 8th Edition of TNM Staging of Lung Cancer: Pattern of Single Extrathoracic Metastasis and Clinical Outcome. Oncologist. 2019 08; 24(8):e749-e754. PMID: 30696724.
    Citations: 2     Fields:    Translation:Humans
  21. Owonikoko TK, Dahlberg SE, Sica GL, Wagner LI, Wade JL, Srkalovic G, Lash BW, Leach JW, Leal TB, Aggarwal C, Ramalingam SS. Randomized Phase II Trial of Cisplatin and Etoposide in Combination With Veliparib or Placebo for Extensive-Stage Small-Cell Lung Cancer: ECOG-ACRIN 2511 Study. J Clin Oncol. 2019 01 20; 37(3):222-229. PMID: 30523756.
    Citations: 33     Fields:    Translation:HumansCTClinical Trials
  22. West H, Dahlberg S. Clinical Trials, End Points, and Statistics-Measuring and Comparing Cancer Treatments in Practice. JAMA Oncol. 2018 12 01; 4(12):1798. PMID: 30193254.
    Citations: 1     Fields:    Translation:Humans
  23. Oxnard GR, Hu Y, Mileham KF, Husain H, Costa DB, Tracy P, Feeney N, Sholl LM, Dahlberg SE, Redig AJ, Kwiatkowski DJ, Rabin MS, Paweletz CP, Thress KS, Jänne PA. Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol. 2018 11 01; 4(11):1527-1534. PMID: 30073261.
    Citations: 103     Fields:    Translation:Humans
  24. Nishino M, Wakai S, Hida T, Dahlberg SE, Ozaki M, Hatabu H, Tachizaki H, Johnson BE. Automated image analysis tool for tumor volume growth rate to guide precision cancer therapy: EGFR-mutant non-small-cell lung cancer as a paradigm. Eur J Radiol. 2018 Dec; 109:68-76. PMID: 30527314.
    Citations: 3     Fields:    Translation:Humans
  25. Tsao AS, Lindwasser OW, Adjei AA, Adusumilli PS, Beyers ML, Blumenthal GM, Bueno R, Burt BM, Carbone M, Dahlberg SE, de Perrot M, Fennell DA, Friedberg J, Gill RR, Gomez DR, Harpole DH, Hassan R, Hesdorffer M, Hirsch FR, Hmeljak J, Kindler HL, Korn EL, Liu G, Mansfield AS, Nowak AK, Pass HI, Peikert T, Rimner A, Robinson BWS, Rosenzweig KE, Rusch VW, Salgia R, Sepesi B, Simone CB, Sridhara R, Szlosarek P, Taioli E, Tsao MS, Yang H, Zauderer MG, Malik SM. Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. J Thorac Oncol. 2018 11; 13(11):1655-1667. PMID: 30266660.
    Citations: 10     Fields:    Translation:Humans
  26. Le-Rademacher J, Dahlberg S, Lee JJ, Adjei AA, Mandrekar SJ. Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations. J Thorac Oncol. 2018 11; 13(11):1625-1637. PMID: 30194034.
    Citations: 3     Fields:    Translation:Humans
  27. Dahlberg SE, Gray RJ. Pragmatic approaches to address expansion cohort design. Cancer. 2018 08; 124(16):3290-3292. PMID: 29975413.
    Citations:    Fields:    Translation:Humans
  28. Leonardi GC, Gainor JF, Altan M, Kravets S, Dahlberg SE, Gedmintas L, Azimi R, Rizvi H, Riess JW, Hellmann MD, Awad MM. Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. J Clin Oncol. 2018 07 01; 36(19):1905-1912. PMID: 29746230.
    Citations: 66     Fields:    Translation:Humans
  29. Kravets S, Dahlberg SE. Interpretation of Results from Under-accruing Studies. Oncologist. 2018 07; 23(7):755-756. PMID: 29739894.
    Citations:    Fields:    Translation:Humans
  30. Yin J, Dahlberg SE, Mandrekar SJ. Evaluation of End Points in Cancer Clinical Trials. J Thorac Oncol. 2018 06; 13(6):745-747. PMID: 29706308.
    Citations: 2     Fields:    Translation:Humans
  31. Russell-Goldman E, Kravets S, Dahlberg SE, Sholl LM, Vivero M. Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas. Cancer Cytopathol. 2018 04; 126(4):253-263. PMID: 29405663.
    Citations: 17     Fields:    Translation:Humans
  32. Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2017 12; 18(12):1610-1623. PMID: 29129443.
    Citations: 26     Fields:    Translation:HumansCTClinical Trials
  33. Nishino M, Dahlberg SE, Adeni AE, Lydon CA, Hatabu H, Jänne PA, Hodi FS, Awad MM. Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. Clin Cancer Res. 2017 Oct 01; 23(19):5737-5744. PMID: 28679767.
    Citations: 20     Fields:    Translation:Humans
  34. Neal JW, Dahlberg SE, Wakelee HA, Aisner SC, Bowden M, Huang Y, Carbone DP, Gerstner GJ, Lerner RE, Rubin JL, Owonikoko TK, Stella PJ, Steen PD, Khalid AA, Ramalingam SS. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial. Lancet Oncol. 2016 Dec; 17(12):1661-1671. PMID: 27825638.
    Citations: 36     Fields:    Translation:HumansCTClinical Trials
  35. Lampson BL, Nishino M, Dahlberg SE, Paul D, Santos AA, Jänne PA, Oxnard GR. Activity of erlotinib when dosed below the maximum tolerated dose for EGFR-mutant lung cancer: Implications for targeted therapy development. Cancer. 2016 Nov 15; 122(22):3456-3463. PMID: 27525836.
    Citations: 5     Fields:    
  36. Sacher AG, Paweletz C, Dahlberg SE, Alden RS, O'Connell A, Feeney N, Mach SL, Jänne PA, Oxnard GR. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. JAMA Oncol. 2016 Aug 01; 2(8):1014-22. PMID: 27055085.
    Citations: 186     Fields:    Translation:Humans
  37. Yanagita M, Redig AJ, Paweletz CP, Dahlberg SE, O'Connell A, Feeney N, Taibi M, Boucher D, Oxnard GR, Johnson BE, Costa DB, Jackman DM, Jänne PA. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial. Clin Cancer Res. 2016 Dec 15; 22(24):6010-6020. PMID: 27281561.
    Citations: 53     Fields:    Translation:HumansCellsCTClinical Trials
  38. Belani CP, Dahlberg SE, Rudin CM, Fleisher M, Chen HX, Takebe N, Velasco MR, Tester WJ, Sturtz K, Hann CL, Shanks JC, Monga M, Ramalingam SS, Schiller JH. Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508). Cancer. 2016 Aug 01; 122(15):2371-8. PMID: 27163943.
    Citations: 22     Fields:    Translation:HumansCellsCTClinical Trials
  39. Fitzgerald C, Patrick M, Gonzalez A, Akin J, Polage CR, Wymore K, Gillim-Ross L, Xavier K, Sadlowski J, Monahan J, Hurd S, Dahlberg S, Jerris R, Watson R, Santovenia M, Mitchell D, Harrison C, Tobin-D'Angelo M, DeMartino M, Pentella M, Razeq J, Leonard C, Jung C, Achong-Bowe R, Evans Y, Jain D, Juni B, Leano F, Robinson T, Smith K, Gittelman RM, Garrigan C, Nachamkin I. Multicenter Evaluation of Clinical Diagnostic Methods for Detection and Isolation of Campylobacter spp. from Stool. J Clin Microbiol. 2016 05; 54(5):1209-15. PMID: 26962088.
    Citations: 11     Fields:    Translation:HumansCells
  40. Sacher AG, Dahlberg SE, Heng J, Mach S, Jänne PA, Oxnard GR. Association Between Younger Age and Targetable Genomic Alterations and Prognosis in Non-Small-Cell Lung Cancer. JAMA Oncol. 2016 Mar; 2(3):313-20. PMID: 26720421.
    Citations: 52     Fields:    Translation:Humans
  41. Redig AJ, Capelletti M, Dahlberg SE, Sholl LM, Mach S, Fontes C, Shi Y, Chalasani P, Jänne PA. Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer. Clin Cancer Res. 2016 07 01; 22(13):3148-56. PMID: 26861459.
    Citations: 25     Fields:    Translation:HumansCells
  42. Nishino M, Dahlberg SE, Fulton LE, Digumarthy SR, Hatabu H, Johnson BE, Sequist LV. Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib. Acad Radiol. 2016 Mar; 23(3):329-36. PMID: 26776293.
    Citations: 9     Fields:    Translation:Humans
  43. Awad MM, Oxnard GR, Jackman DM, Savukoski DO, Hall D, Shivdasani P, Heng JC, Dahlberg SE, Jänne PA, Verma S, Christensen J, Hammerman PS, Sholl LM. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. J Clin Oncol. 2016 Mar 01; 34(7):721-30. PMID: 26729443.
    Citations: 130     Fields:    Translation:Humans
  44. Lin JJ, Cardarella S, Lydon CA, Dahlberg SE, Jackman DM, Jänne PA, Johnson BE. Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs. J Thorac Oncol. 2016 Apr; 11(4):556-65. PMID: 26724471.
    Citations: 79     Fields:    Translation:Humans
  45. Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Chaft J, Malik S, Mooney M, Abrams JS, Jänne PA, Gandara DR, Ramalingam SS, Vokes EE. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. Clin Cancer Res. 2015 Dec 15; 21(24):5439-44. PMID: 26672084.
    Citations: 30     Fields:    Translation:Humans
  46. Calles A, Liao X, Sholl LM, Rodig SJ, Freeman GJ, Butaney M, Lydon C, Dahlberg SE, Hodi FS, Oxnard GR, Jackman DM, Jänne PA. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer. J Thorac Oncol. 2015 Dec; 10(12):1726-35. PMID: 26473645.
    Citations: 60     Fields:    Translation:Humans
  47. Foster NR, Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara DR, Shibata T, Saijo N, Vokes EE, Adjei AA, Mandrekar SJ. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. J Thorac Oncol. 2015 Jul; 10(7):1099-106. PMID: 26134227.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  48. Owonikoko TK, Dahlberg SE, Khan SA, Gerber DE, Dowell J, Moss RA, Belani CP, Hann CL, Aggarwal C, Ramalingam SS. A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511). Lung Cancer. 2015 Jul; 89(1):66-70. PMID: 25985977.
    Citations: 21     Fields:    Translation:HumansCTClinical Trials
  49. Lo PC, Dahlberg SE, Nishino M, Johnson BE, Sequist LV, Jackman DM, Jänne PA, Oxnard GR. Delay of treatment change after objective progression on first-line erlotinib in epidermal growth factor receptor-mutant lung cancer. Cancer. 2015 Aug 01; 121(15):2570-7. PMID: 25876525.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  50. Hanna NH, Dahlberg SE, Kolesar JM, Aggarwal C, Hirsch FR, Ramalingam SS, Schiller JH. Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative Oncology Group (ECOG) study (E4508). Cancer. 2015 Jul 01; 121(13):2253-61. PMID: 25740387.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  51. Calles A, Sholl LM, Rodig SJ, Pelton AK, Hornick JL, Butaney M, Lydon C, Dahlberg SE, Oxnard GR, Jackman DM, Jänne PA. Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS-Mutant Lung Adenocarcinoma. Clin Cancer Res. 2015 Jun 15; 21(12):2851-60. PMID: 25737507.
    Citations: 30     Fields:    Translation:HumansCells
  52. Nishino M, Cardarella S, Dahlberg SE, Araki T, Lydon C, Jackman DM, Rabin MS, Hatabu H, Johnson BE. Interstitial lung abnormalities in treatment-naïve advanced non-small-cell lung cancer patients are associated with shorter survival. Eur J Radiol. 2015 May; 84(5):998-1004. PMID: 25726730.
    Citations: 18     Fields:    Translation:Humans
  53. Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, Dahlberg SE, Huberman MS, Costa DB. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 2015 Apr; 88(1):108-11. PMID: 25682925.
    Citations: 100     Fields:    Translation:Humans
  54. Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1):S1-63. PMID: 25535693.
    Citations: 40     Fields:    Translation:Humans
  55. Mandrekar SJ, Dahlberg SE, Simon R. Improving Clinical Trial Efficiency: Thinking outside the Box. Am Soc Clin Oncol Educ Book. 2015; e141-7. PMID: 25993165.
    Citations: 21     Fields:    Translation:Humans
  56. DeAngelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG, Amrein PC, Ballen KK, Seftel MD, Turner AR, Leber B, Howson-Jan K, Kelly K, Cohen S, Matthews JH, Savoie L, Wadleigh M, Sirulnik LA, Galinsky I, Neuberg DS, Sallan SE, Stone RM. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015 Mar; 29(3):526-34. PMID: 25079173.
    Citations: 72     Fields:    Translation:HumansCTClinical Trials
  57. Dahlberg SE, Shapiro GI, Clark JW, Johnson BE. Evaluation of statistical designs in phase I expansion cohorts: the Dana-Farber/Harvard Cancer Center experience. J Natl Cancer Inst. 2014 Jul; 106(7). PMID: 24963024.
    Citations: 19     Fields:    Translation:Humans
  58. Pillai RN, Aisner J, Dahlberg SE, Rogers JS, DiPaola RS, Aisner S, Ramalingam SS, Schiller JH. Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501). Cancer Chemother Pharmacol. 2014 Jul; 74(1):177-83. PMID: 24858462.
    Citations: 8     Fields:    Translation:HumansCellsCTClinical Trials
  59. Owonikoko TK, Aisner J, Wang XV, Dahlberg SE, Rubin EH, Ramalingam SS, Gounder M, Rausch PG, Axelrod RS, Schiller JH. E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer. Cancer Chemother Pharmacol. 2014 Jan; 73(1):171-80. PMID: 24288121.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  60. Lo RC, Bensley RP, Dahlberg SE, Matyal R, Hamdan AD, Wyers M, Chaikof EL, Schermerhorn ML. Presentation, treatment, and outcome differences between men and women undergoing revascularization or amputation for lower extremity peripheral arterial disease. J Vasc Surg. 2014 Feb; 59(2):409-418.e3. PMID: 24080134.
    Citations: 26     Fields:    Translation:Humans
  61. Dahlberg SE, Schiller JH, Bonomi PB, Sandler AB, Brahmer JR, Ramalingam SS, Johnson DH. Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials. J Thorac Oncol. 2013 Sep; 8(9):1121-7. PMID: 23887169.
    Citations: 33     Fields:    Translation:Humans
  62. Wright AA, Howitt BE, Myers AP, Dahlberg SE, Palescandolo E, Van Hummelen P, MacConaill LE, Shoni M, Wagle N, Jones RT, Quick CM, Laury A, Katz IT, Hahn WC, Matulonis UA, Hirsch MS. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 2013 Nov 01; 119(21):3776-83. PMID: 24037752.
    Citations: 79     Fields:    Translation:Humans
  63. Gerber DE, Dahlberg SE, Sandler AB, Ahn DH, Schiller JH, Brahmer JR, Johnson DH. Baseline tumour measurements predict survival in advanced non-small cell lung cancer. Br J Cancer. 2013 Sep 17; 109(6):1476-81. PMID: 23942074.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  64. Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Ramaiya NH, Hatabu H, Jänne PA, Johnson BE. Volumetric tumor growth in advanced non-small cell lung cancer patients with EGFR mutations during EGFR-tyrosine kinase inhibitor therapy: developing criteria to continue therapy beyond RECIST progression. Cancer. 2013 Nov 01; 119(21):3761-8. PMID: 23922022.
    Citations: 18     Fields:    Translation:Humans
  65. Glaser JD, Bensley RP, Hurks R, Dahlberg S, Hamdan AD, Wyers MC, Chaikof EL, Schermerhorn ML. Fate of the contralateral limb after lower extremity amputation. J Vasc Surg. 2013 Dec; 58(6):1571-1577.e1. PMID: 23921246.
    Citations: 6     Fields:    Translation:Humans
  66. Nishino M, Dahlberg SE, Cardarella S, Jackman DM, Rabin MS, Hatabu H, Jänne PA, Johnson BE. Tumor volume decrease at 8 weeks is associated with longer survival in EGFR-mutant advanced non-small-cell lung cancer patients treated with EGFR TKI. J Thorac Oncol. 2013 Aug; 8(8):1059-68. PMID: 23787800.
    Citations: 16     Fields:    Translation:Humans
  67. Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, Lee H, Whalen C, Tyburski K, Winer E, Ivy P, Matulonis UA. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013 Sep; 49(14):2972-8. PMID: 23810467.
    Citations: 51     Fields:    Translation:HumansCTClinical Trials
  68. Mauguen A, Pignon JP, Burdett S, Domerg C, Fisher D, Paulus R, Mandrekar SJ, Belani CP, Shepherd FA, Eisen T, Pang H, Collette L, Sause WT, Dahlberg SE, Crawford J, O'Brien M, Schild SE, Parmar M, Tierney JF, Le Pechoux C, Michiels S. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. Lancet Oncol. 2013 Jun; 14(7):619-26. PMID: 23680111.
    Citations: 49     Fields:    Translation:Humans
  69. Hoang T, Dahlberg SE, Schiller JH, Johnson DH. Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594. Lung Cancer. 2013 Jul; 81(1):47-52. PMID: 23611404.
    Citations: 4     Fields:    Translation:Humans
  70. Oxnard GR, Lo PC, Nishino M, Dahlberg SE, Lindeman NI, Butaney M, Jackman DM, Johnson BE, Jänne PA. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013 Feb; 8(2):179-84. PMID: 23328547.
    Citations: 66     Fields:    Translation:HumansCells
  71. Lo RC, Darling J, Bensley RP, Giles KA, Dahlberg SE, Hamdan AD, Wyers M, Schermerhorn ML. Outcomes following infrapopliteal angioplasty for critical limb ischemia. J Vasc Surg. 2013 Jun; 57(6):1455-63; discussion 1463-4. PMID: 23375610.
    Citations: 15     Fields:    Translation:Humans
  72. Vrooman LM, Stevenson KE, Supko JG, O'Brien J, Dahlberg SE, Asselin BL, Athale UH, Clavell LA, Kelly KM, Kutok JL, Laverdière C, Lipshultz SE, Michon B, Schorin M, Relling MV, Cohen HJ, Neuberg DS, Sallan SE, Silverman LB. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol. 2013 Mar 20; 31(9):1202-10. PMID: 23358966.
    Citations: 89     Fields:    Translation:HumansCells
  73. Nishino M, Cardarella S, Dahlberg SE, Jackman DM, Ramaiya NH, Hatabu H, Rabin MS, Jänne PA, Johnson BE. Radiographic assessment and therapeutic decisions at RECIST progression in EGFR-mutant NSCLC treated with EGFR tyrosine kinase inhibitors. Lung Cancer. 2013 Mar; 79(3):283-8. PMID: 23254265.
    Citations: 22     Fields:    Translation:HumansCTClinical Trials
  74. Lipshultz SE, Miller TL, Lipsitz SR, Neuberg DS, Dahlberg SE, Colan SD, Silverman LB, Henkel JM, Franco VI, Cushman LL, Asselin BL, Clavell LA, Athale U, Michon B, Laverdière C, Schorin MA, Larsen E, Usmani N, Sallan SE. Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes. Pediatrics. 2012 Dec; 130(6):1003-11. PMID: 23166343.
    Citations: 35     Fields:    Translation:Humans
  75. Hoang T, Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab. J Thorac Oncol. 2012 Sep; 7(9):1361-8. PMID: 22843087.
    Citations: 31     Fields:    Translation:Humans
  76. Shin J, Padmanabhan A, de Groh ED, Lee JS, Haidar S, Dahlberg S, Guo F, He S, Wolman MA, Granato M, Lawson ND, Wolfe SA, Kim SH, Solnica-Krezel L, Kanki JP, Ligon KL, Epstein JA, Look AT. Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development. Dis Model Mech. 2012 Nov; 5(6):881-94. PMID: 22773753.
    Citations: 29     Fields:    Translation:AnimalsCells
  77. Mauguen A, Le Péchoux C, Saunders MI, Schild SE, Turrisi AT, Baumann M, Sause WT, Ball D, Belani CP, Bonner JA, Zajusz A, Dahlberg SE, Nankivell M, Mandrekar SJ, Paulus R, Behrendt K, Koch R, Bishop JF, Dische S, Arriagada R, De Ruysscher D, Pignon JP. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol. 2012 Aug 01; 30(22):2788-97. PMID: 22753901.
    Citations: 64     Fields:    Translation:Humans
  78. Kentsis A, Reed C, Rice KL, Sanda T, Rodig SJ, Tholouli E, Christie A, Valk PJ, Delwel R, Ngo V, Kutok JL, Dahlberg SE, Moreau LA, Byers RJ, Christensen JG, Vande Woude G, Licht JD, Kung AL, Staudt LM, Look AT. Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia. Nat Med. 2012 Jul; 18(7):1118-22. PMID: 22683780.
    Citations: 79     Fields:    Translation:HumansAnimalsCells
  79. Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, Colan SD, Neuberg DS, Dahlberg SE, Henkel JM, Asselin BL, Athale UH, Clavell LA, Laverdière C, Michon B, Schorin MA, Sallan SE. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012 Apr 01; 30(10):1042-9. PMID: 22370326.
    Citations: 90     Fields:    Translation:Humans
  80. Hoang T, Dahlberg SE, Schiller JH, Mehta MP, Fitzgerald TJ, Belinsky SA, Johnson DH. Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. J Clin Oncol. 2012 Feb 20; 30(6):616-22. PMID: 22271472.
    Citations: 19     Fields:    Translation:HumansCTClinical Trials
  81. Wakelee HA, Dahlberg SE, Brahmer JR, Schiller JH, Perry MC, Langer CJ, Sandler AB, Belani CP, Johnson DH. Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. Lung Cancer. 2012 Jun; 76(3):410-5. PMID: 22266041.
    Citations: 6     Fields:    Translation:Humans
  82. Weigert O, Kopp N, Lane AA, Yoda A, Dahlberg SE, Neuberg D, Bahar AY, Chapuy B, Kutok JL, Longtine JA, Kuo FC, Haley T, Salois M, Sullivan TJ, Fisher DC, Fox EA, Rodig SJ, Antin JH, Weinstock DM. Molecular ontogeny of donor-derived follicular lymphomas occurring after hematopoietic cell transplantation. Cancer Discov. 2012 Jan; 2(1):47-55. PMID: 22585168.
    Citations: 25     Fields:    Translation:Humans
  83. Tessema M, Yingling CM, Thomas CL, Klinge DM, Bernauer AM, Liu Y, Dacic S, Siegfried JM, Dahlberg SE, Schiller JH, Belinsky SA. SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15. Oncogene. 2012 Sep 13; 31(37):4107-16. PMID: 22158045.
    Citations: 27     Fields:    Translation:HumansAnimalsCells
  84. Gutierrez A, Kentsis A, Sanda T, Holmfeldt L, Chen SC, Zhang J, Protopopov A, Chin L, Dahlberg SE, Neuberg DS, Silverman LB, Winter SS, Hunger SP, Sallan SE, Zha S, Alt FW, Downing JR, Mullighan CG, Look AT. The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. Blood. 2011 Oct 13; 118(15):4169-73. PMID: 21878675.
    Citations: 79     Fields:    Translation:HumansCellsCTClinical Trials
  85. Gutierrez A, Grebliunaite R, Feng H, Kozakewich E, Zhu S, Guo F, Payne E, Mansour M, Dahlberg SE, Neuberg DS, den Hertog J, Prochownik EV, Testa JR, Harris M, Kanki JP, Look AT. Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. J Exp Med. 2011 Aug 01; 208(8):1595-603. PMID: 21727187.
    Citations: 46     Fields:    Translation:AnimalsCells
  86. Mrakotsky CM, Silverman LB, Dahlberg SE, Alyman MC, Sands SA, Queally JT, Miller TP, Cranston A, Neuberg DS, Sallan SE, Waber DP. Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. Pediatr Blood Cancer. 2011 Sep; 57(3):492-8. PMID: 21560226.
    Citations: 12     Fields:    Translation:Humans
  87. Kolesar JM, Dahlberg SE, Marsh S, McLeod HL, Johnson DH, Keller SM, Schiller JH. The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer. Oncol Rep. 2011 Jun; 25(6):1765-72. PMID: 21479364.
    Citations: 11     Fields:    Translation:Humans
  88. Grace RF, Dahlberg SE, Neuberg D, Sallan SE, Connors JM, Neufeld EJ, Deangelo DJ, Silverman LB. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011 Feb; 152(4):452-9. PMID: 21210774.
    Citations: 44     Fields:    Translation:Humans
  89. Brahmer JR, Dahlberg SE, Gray RJ, Schiller JH, Perry MC, Sandler A, Johnson DH. Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599. J Thorac Oncol. 2011 Jan; 6(1):103-8. PMID: 21079521.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  90. Sandler A, Yi J, Dahlberg S, Kolb MM, Wang L, Hambleton J, Schiller J, Johnson DH. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thorac Oncol. 2010 Sep; 5(9):1416-23. PMID: 20686429.
    Citations: 44     Fields:    Translation:HumansCTClinical Trials
  91. Gutierrez A, Dahlberg SE, Neuberg DS, Zhang J, Grebliunaite R, Sanda T, Protopopov A, Tosello V, Kutok J, Larson RS, Borowitz MJ, Loh ML, Ferrando AA, Winter SS, Mullighan CG, Silverman LB, Chin L, Hunger SP, Sallan SE, Look AT. Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. J Clin Oncol. 2010 Aug 20; 28(24):3816-23. PMID: 20644084.
    Citations: 33     Fields:    Translation:Humans
  92. Aisner SC, Dahlberg S, Hameed MR, Ettinger DS, Schiller JH, Johnson DH, Aisner J, Loehrer PJ. Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Oncology Group study. J Thorac Oncol. 2010 Jun; 5(6):885-92. PMID: 20421818.
    Citations: 10     Fields:    Translation:Humans
  93. Gutierrez A, Sanda T, Ma W, Zhang J, Grebliunaite R, Dahlberg S, Neuberg D, Protopopov A, Winter SS, Larson RS, Borowitz MJ, Silverman LB, Chin L, Hunger SP, Jamieson C, Sallan SE, Look AT. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood. 2010 Apr 08; 115(14):2845-51. PMID: 20124220.
    Citations: 54     Fields:    Translation:Humans
  94. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol. 2010 Feb 20; 28(6):949-54. PMID: 20085937.
    Citations: 71     Fields:    Translation:HumansCTClinical Trials
  95. Horn L, Dahlberg SE, Sandler AB, Dowlati A, Moore DF, Murren JR, Schiller JH. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol. 2009 Dec 10; 27(35):6006-11. PMID: 19826110.
    Citations: 47     Fields:    Translation:HumansCTClinical Trials
  96. Giles KA, Hamdan AD, Pomposelli FB, Wyers MC, Dahlberg SE, Schermerhorn ML. Population-based outcomes following endovascular and open repair of ruptured abdominal aortic aneurysms. J Endovasc Ther. 2009 Oct; 16(5):554-64. PMID: 19842719.
    Citations: 15     Fields:    Translation:HumansPHPublic Health
  97. Kearney SL, Dahlberg SE, Levy DE, Voss SD, Sallan SE, Silverman LB. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2009 Aug; 53(2):162-7. PMID: 19405141.
    Citations: 30     Fields:    Translation:Humans
  98. Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y, Dahlberg S, Neuberg D, Moreau LA, Winter SS, Larson R, Zhang J, Protopopov A, Chin L, Pandolfi PP, Silverman LB, Hunger SP, Sallan SE, Look AT. High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009 Jul 16; 114(3):647-50. PMID: 19458356.
    Citations: 167     Fields:    Translation:HumansCells
  99. Simosa HF, Pomposelli FB, Dahlberg S, Scali ST, Hamdan AD, Schermerhorn ML. Predictors of failure after angioplasty of infrainguinal vein bypass grafts. J Vasc Surg. 2009 Jan; 49(1):117-21. PMID: 19028063.
    Citations: 2     Fields:    Translation:Humans
  100. Dahlberg SE, Gray RJ, Johnson BE. Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal. J Clin Oncol. 2008 Sep 10; 26(26):4233-5. PMID: 18779608.
    Citations: 1     Fields:    Translation:Humans
  101. Barry EV, Vrooman LM, Dahlberg SE, Neuberg DS, Asselin BL, Athale UH, Clavell LA, Larsen EC, Moghrabi A, Samson Y, Schorin MA, Cohen HJ, Lipshultz SE, Sallan SE, Silverman LB. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol. 2008 Mar 01; 26(7):1106-11. PMID: 18309945.
    Citations: 42     Fields:    Translation:Humans
  102. Ramalingam SS, Dahlberg SE, Langer CJ, Gray R, Belani CP, Brahmer JR, Sandler AB, Schiller JH, Johnson DH. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol. 2008 Jan 01; 26(1):60-5. PMID: 18165641.
    Citations: 91     Fields:    Translation:Humans
  103. Dahlberg SE, Wang M. A proportional hazards cure model for the analysis of time to event with frequently unidentifiable causes. Biometrics. 2007 Dec; 63(4):1237-44. PMID: 18078485.
    Citations: 1     Fields:    Translation:Humans
  104. Pandya KJ, Dahlberg S, Hidalgo M, Cohen RB, Lee MW, Schiller JH, Johnson DH. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J Thorac Oncol. 2007 Nov; 2(11):1036-41. PMID: 17975496.
    Citations: 59     Fields:    Translation:HumansCTClinical Trials
  105. Nelson AL, Ries J, Bagnoli F, Dahlberg S, Fälker S, Rounioja S, Tschöp J, Morfeldt E, Ferlenghi I, Hilleringmann M, Holden DW, Rappuoli R, Normark S, Barocchi MA, Henriques-Normark B. RrgA is a pilus-associated adhesin in Streptococcus pneumoniae. Mol Microbiol. 2007 Oct; 66(2):329-40. PMID: 17850254.
    Citations: 74     Fields:    Translation:HumansAnimalsCells
  106. Patel VI, Hamdan AD, Schermerhorn ML, Hile C, Dahlberg S, Campbell DR, LoGerfo FW, Pomposelli FB. Lower extremity arterial revascularization in obese patients. J Vasc Surg. 2007 Oct; 46(4):738-42. PMID: 17764878.
    Citations: 6     Fields:    Translation:Humans
  107. Zhou J, Goldwasser MA, Li A, Dahlberg SE, Neuberg D, Wang H, Dalton V, McBride KD, Sallan SE, Silverman LB, Gribben JG. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01. Blood. 2007 Sep 01; 110(5):1607-11. PMID: 17485550.
    Citations: 38     Fields:    Translation:Humans
  108. Szwarc SE, Bonetti M. Modelling menstrual status during and after adjuvant treatment for breast cancer. Stat Med. 2006 Oct 30; 25(20):3534-47. PMID: 16345025.
    Citations: 3     Fields:    Translation:Humans
  109. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutré S, Dahlberg S, Ellison R, Warrell RP. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001 Sep 15; 19(18):3852-60. PMID: 11559723.
    Citations: 176     Fields:    Translation:HumansCTClinical Trials
  110. List AF, Maziarz R, Stiff P, Jansen J, Liesveld J, Andrews F, Schuster M, Wolff S, Litzow M, Karanes C, Dahlberg S, Kirkhart B, Bianco JA, Singer JW. A randomized placebo-controlled trial of lisofylline in HLA-identical, sibling-donor, allogeneic bone marrow transplant recipients. The Lisofylline Marrow Transplant Study Group. Bone Marrow Transplant. 2000 Feb; 25(3):283-91. PMID: 10673700.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  111. Moore DF, Brown TD, LeBlanc M, Dahlberg S, Miller TP, McClure S, Fisher RI. Phase II trial of menogaril in non-Hodgkin's lymphomas: a Southwest Oncology Group trial. Invest New Drugs. 1999; 17(2):169-72. PMID: 10638487.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  112. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med. 1998 Jul 02; 339(1):21-6. PMID: 9647875.
    Citations: 152     Fields:    Translation:HumansCTClinical Trials
  113. Stiff PJ, Dahlberg S, Forman SJ, McCall AR, Horning SJ, Nademanee AP, Blume KG, LeBlanc M, Fisher RI. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial. J Clin Oncol. 1998 Jan; 16(1):48-55. PMID: 9440722.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  114. Emlein G, Villegas B, Dahlberg S, Leppo J. Left ventricular cavity size determined by preoperative dipyridamole thallium scintigraphy as a predictor of late cardiac events in vascular surgery patients. Am Heart J. 1996 May; 131(5):907-14. PMID: 8615309.
    Citations: 4     Fields:    Translation:Humans
  115. Liu PY, Dahlberg S. Design and analysis of multiarm clinical trials with survival endpoints. Control Clin Trials. 1995 Apr; 16(2):119-30. PMID: 7789135.
    Citations: 4     Fields:    Translation:Humans
  116. Fisher RI, Dahlberg S, Nathwani BN, Banks PM, Miller TP, Grogan TM. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood. 1995 Feb 15; 85(4):1075-82. PMID: 7849295.
    Citations: 40     Fields:    Translation:HumansCTClinical Trials
  117. Fabian CJ, Mansfield CM, Dahlberg S, Jones SE, Miller TP, Van Slyck E, Grozea PN, Morrison FS, Coltman CA, Fisher RI. Low-dose involved field radiation after chemotherapy in advanced Hodgkin disease. A Southwest Oncology Group randomized study. Ann Intern Med. 1994 Jun 01; 120(11):903-12. PMID: 8172436.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  118. Miller TP, Grogan TM, Dahlberg S, Spier CM, Braziel RM, Banks PM, Foucar K, Kjeldsberg CR, Levy N, Nathwani BN, et al. Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood. 1994 Mar 15; 83(6):1460-6. PMID: 8123837.
    Citations: 50     Fields:    Translation:HumansCTClinical Trials
  119. Saez R, Dahlberg S, Appelbaum FR, Hartsock RJ, Lemaistre F, Coltman CA, Fisher RI. Autologous bone marrow transplantation in adults with non-Hodgkin's lymphoma: a Southwest Oncology Group study. Hematol Oncol. 1994 Mar-Apr; 12(2):75-85. PMID: 8070756.
    Citations: 2     Fields:    Translation:Humans
  120. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP. A phase III comparison of CHOP vs. m-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patients with intermediate- or high-grade non-Hodgkin's lymphoma: results of SWOG-8516 (Intergroup 0067), the National High-Priority Lymphoma Study. Ann Oncol. 1994; 5 Suppl 2:91-5. PMID: 7515652.
    Citations: 13     Fields:    Translation:HumansCTClinical Trials
  121. Liu PY, Dahlberg S, Crowley J. Selection designs for pilot studies based on survival. Biometrics. 1993 Jun; 49(2):391-8. PMID: 8369375.
    Citations: 10     Fields:    Translation:Humans
  122. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993 Apr 08; 328(14):1002-6. PMID: 7680764.
    Citations: 306     Fields:    Translation:HumansCTClinical Trials
  123. Dana BW, Dahlberg S, Nathwani BN, Chase E, Coltman C, Miller TP, Fisher RI. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol. 1993 Apr; 11(4):644-51. PMID: 8478660.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  124. Alberts DS, Dahlberg S, Green SJ, Garcia D, Hannigan EV, O'Toole R, Stock-Novack D, Surwit EA, Malviya VK, Jolles CJ. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study. Cancer. 1993 Jan 15; 71(2 Suppl):618-27. PMID: 8420685.
    Citations: 11     Fields:    Translation:HumansCTClinical Trials
  125. Miller TP, Dahlberg S. Treatment of diffuse large-cell lymphoma: a summary of outcome for patients treated by Southwest Oncology Group. Cancer Treat Res. 1993; 66:53-63. PMID: 8102863.
    Citations: 2     Fields:    Translation:Humans
  126. Mittleman RS, Candinas R, Dahlberg S, Vander Salm T, Moran JM, Huang SK. Predictors of surgical mortality and long-term results of endocardial resection for drug-refractory ventricular tachycardia. Am Heart J. 1992 Nov; 124(5):1226-32. PMID: 1442490.
    Citations: 1     Fields:    Translation:Humans
  127. Green SJ, Dahlberg S. Planned versus attained design in phase II clinical trials. Stat Med. 1992 May; 11(7):853-62. PMID: 1604065.
    Citations: 57     Fields:    Translation:Humans
  128. Dahlberg S, Liu PY. Prognostic factors in clinical trials. Breast Cancer Res Treat. 1992; 22(3):193-6. PMID: 1391985.
    Citations: 2     Fields:    Translation:Humans
  129. Miller TP, Dahlberg S, Salmon SE, Williamson SK, Belt RJ, Dana BW, Fisher RI. Activity of esorubicin in recurrent malignant lymphoma: a Southwest Oncology Group study. J Clin Oncol. 1991 Jul; 9(7):1204-9. PMID: 2045860.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  130. Dahlberg S, Miller TP, Fisher RI. A clinical phase II study of ProMACE-CytaBOM. J Clin Oncol. 1991 May; 9(5):888. PMID: 1707958.
    Citations:    Fields:    Translation:Humans
  131. Weick JK, Dahlberg S, Fisher RI, Dana B, Miller TP, Balcerzak SP, Pierce HI. Combination chemotherapy of intermediate-grade and high-grade non-Hodgkin's lymphoma with MACOP-B: a Southwest Oncology Group study. J Clin Oncol. 1991 May; 9(5):748-53. PMID: 1707955.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  132. Dabich L, Dahlberg S, Hartsock RJ, LoBuglio AF, Liepman MK, Grozea PN, Eyre HJ, Weick JK, Bonnet JD, Coltman CA, et al. Alternated versus syncopated CHOP-PVB: two studies for the treatment of non-Hodgkin's lymphoma by the Southwest Oncology Group. Cancer Invest. 1991; 9(6):613-20. PMID: 1721000.
    Citations:    Fields:    Translation:HumansCTClinical Trials
  133. Miller TP, Dahlberg S, Weick JK, Files JC, Eyre HJ, Pendergrass KB, Fisher RI. Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study. J Clin Oncol. 1990 Dec; 8(12):1951-8. PMID: 1700079.
    Citations: 5     Fields:    Translation:HumansCTClinical Trials
  134. Von Hoff DD, Dahlberg S, Hartstock RJ, Eyre HJ. Activity of fludarabine monophosphate in patients with advanced mycosis fungoides: a Southwest Oncology Group study. J Natl Cancer Inst. 1990 Aug 15; 82(16):1353-5. PMID: 1696322.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  135. Dana BW, Dahlberg S, Miller TP, Hartsock RJ, Balcerzak S, Coltman CA, Carden JO, Hartley K, Fisher RI. m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial. J Clin Oncol. 1990 Jul; 8(7):1155-62. PMID: 1694233.
    Citations: 2     Fields:    Translation:Humans
  136. Mills GM, Dahlberg S, Cowan J, Neilan BA, Gumbart CH, Hussein K, Coltman CA. Phase II evaluation of bisantrene in acute leukemia. A Southwest Oncology Group Study. Am J Clin Oncol. 1989 Dec; 12(6):507-10. PMID: 2589232.
    Citations:    Fields:    Translation:Humans
  137. Dana B, Dahlberg S, Schnitzer B, Kjeldsberg CR, Jones SE, Carden J, Mundis R, Tranum B. Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: a Southwest Oncology Group phase II trial. Invest New Drugs. 1989 Jul; 7(2-3):247-50. PMID: 2793382.
    Citations: 1     Fields:    Translation:Humans
  138. Tallman MS, Kopecky KJ, Amos D, Dahlberg S, Hewlett JS, Files JC, Coltman CA, Thomas ED, Appelbaum FR. Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission. J Clin Oncol. 1989 Mar; 7(3):326-37. PMID: 2645386.
    Citations: 2     Fields:    Translation:Humans
  139. Hussein KK, Dahlberg S, Head D, Waddell CC, Dabich L, Weick JK, Morrison F, Saiki JH, Metz E, Rivkin SE, et al. Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy. Blood. 1989 Jan; 73(1):57-63. PMID: 2642717.
    Citations: 16     Fields:    Translation:HumansCTClinical Trials
  140. Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S, Deeg HJ, Sanders JE, Doney KC, Appelbaum FR, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988 Aug; 72(2):546-54. PMID: 3042041.
    Citations: 50     Fields:    Translation:HumansCTClinical Trials
  141. Sullivan KM, Witherspoon RP, Storb R, Deeg HJ, Dahlberg S, Sanders JE, Appelbaum FR, Doney KC, Weiden P, Anasetti C, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood. 1988 Aug; 72(2):555-61. PMID: 3042042.
    Citations: 28     Fields:    Translation:Humans
  142. Miller TP, Dana BW, Weick JK, Jones SE, Coltman CA, Dahlberg S, Fisher RI. Southwest Oncology Group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Semin Hematol. 1988 Apr; 25(2 Suppl 2):17-22. PMID: 2456619.
    Citations: 2     Fields:    Translation:Humans
  143. Fisher RI, Miller TP, Dana BW, Jones SE, Dahlberg S, Coltman CA. Southwest oncology group clinical trials for intermediate- and high-grade non-Hodgkin's lymphomas. Semin Hematol. 1987 Apr; 24(2 Suppl 1):21-5. PMID: 2438778.
    Citations: 6     Fields:    Translation:HumansCTClinical Trials
  144. Davis S, Dahlberg S, Myers MH, Chen A, Steinhorn SC. Hodgkin's disease in the United States: a comparison of patient characteristics and survival in the Centralized Cancer Patient Data System and the Surveillance, Epidemiology, and End Results Program. J Natl Cancer Inst. 1987 Mar; 78(3):471-8. PMID: 3469461.
    Citations: 9     Fields:    Translation:Humans
  145. Hill RS, Petersen FB, Storb R, Appelbaum FR, Doney K, Dahlberg S, Ramberg R, Thomas ED. Mixed hematologic chimerism after allogeneic marrow transplantation for severe aplastic anemia is associated with a higher risk of graft rejection and a lessened incidence of acute graft-versus-host disease. Blood. 1986 Mar; 67(3):811-6. PMID: 3511988.
    Citations: 18     Fields:    Translation:Humans
  146. Dayal HH, Polissar L, Dahlberg S. Race, socioeconomic status, and other prognostic factors for survival from prostate cancer. J Natl Cancer Inst. 1985 May; 74(5):1001-6. PMID: 3858570.
    Citations: 18     Fields:    Translation:Humans
  147. Loughran TP, Deeg HJ, Dahlberg S, Kennedy MS, Storb R, Thomas ED. Incidence of hypertension after marrow transplantation among 112 patients randomized to either cyclosporine or methotrexate as graft-versus-host disease prophylaxis. Br J Haematol. 1985 Mar; 59(3):547-53. PMID: 3882141.
    Citations: 9     Fields:    Translation:HumansCTClinical Trials
  148. Appelbaum FR, Dahlberg S, Thomas ED, Buckner CD, Cheever MA, Clift RA, Crowley J, Deeg HJ, Fefer A, Greenberg PD, et al. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Intern Med. 1984 Nov; 101(5):581-8. PMID: 6385797.
    Citations: 23     Fields:    Translation:HumansCTClinical Trials
  149. Farewell VT, Dahlberg S. Some statistical methodology for the analysis of HLA data. Biometrics. 1984 Jun; 40(2):547-60. PMID: 6487730.
    Citations: 4     Fields:    Translation:Humans
  150. Polissar L, Feigl P, Lane WW, Glaefke G, Dahlberg S. Accuracy of basic cancer patient data: results from an extensive recoding survey. J Natl Cancer Inst. 1984 May; 72(5):1007-14. PMID: 6585578.
    Citations: 5     Fields:    Translation:Humans
  151. Doney KC, Torok-Storb B, Dahlberg S, Buckner CD, Martin P, Hansen JA, Thomas ED, Storb R. Immunosuppressive therapy of severe aplastic anemia. Prog Clin Biol Res. 1984; 148:259-70. PMID: 6379664.
    Citations: 3     Fields:    Translation:HumansCellsCTClinical Trials
  152. Sullivan KM, Neiman PE, Kadin ME, Dahlberg S, Farewell VT, Rudolph RH, Bagley CM, Appelbaum FR, Thomas ED. Combined modality therapy of advanced non-Hodgkin's lymphoma: an analysis of remission duration and survival in 95 patients. Blood. 1983 Jul; 62(1):51-61. PMID: 6344932.
    Citations: 4     Fields:    Translation:Humans
  153. Laszlo J, Lenhard R, Dahlberg S, Feigl P. A profile of treatment approaches used at comprehensive cancer centers. J Chronic Dis. 1982; 35(11):853-9. PMID: 6292252.
    Citations: 1     Fields:    Translation:Humans
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact feedbackcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Dahlberg's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (373)
Explore
_
Co-Authors (105)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.